New York ? GlaxoSmithKline PLC, which has been sued by the New York attorney general for fraud for withholding critical clinical information, announced Friday it would post the results of all of its drug trials on the Web.

Glaxo’s announcement comes two weeks after the lawsuit was filed, and three days after an American Medical Assn. resolution called on the government to create a public registry for all drug study results so that unfavorable results also get attention.

Glaxo couldn’t say when the information would be posted but said it shouldn’t take longer than six months.

“I think this is the right thing to do. We think more transparency is better,” said Glaxo chairman and chief executive J.P. Garnier. “We don’t want to be accused of anything about the way we deal with trials. I think it’s too important a subject.”

Garnier said the company had been considering the Web site for months and the decision to announce it was not a reaction to the lawsuit, but to the AMA resolution. Still, he said he hoped the announcement would persuade New York state Atty. Gen. Eliot Spitzer to drop the lawsuit.

Glaxo already has published on its Web site the studies Spitzer accused it of suppressing, along with what Garnier said was proof that the trial results had been made public.

Filed in New York State Supreme Court, the suit said Glaxo suppressed four studies of its anti-depressant Paxil that failed to demonstrate the drug was effective in treating children and adolescents and that suggested a possible increase in suicidal thinking and acts.

Doctors receive much of their information on clinical trials through attending medical meetings, reading journals and drug company marketing. There has long been widespread concern that negative information isn’t communicated through those channels, and such worries have been magnified recently over the issue of prescribing antidepressants for children.